Search

Displaying results 6661 - 6670 of 8194 in total
  1. Drug

    MaxAdFVIII

    go.drugbank.com/drugs/DB17713
    Experimental

    MaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.

  2. Drug

    UM-171

    go.drugbank.com/drugs/DB19449
    Investigational

    UM-171 is a pyrimidoindole derivative that is an agonist of ex vivo hematopoietic stem cell expansion and thus supports the expansion of hematopoietic stem cells.[A264868, A264873]

  3. Drug

    Rebaudioside A

    go.drugbank.com/drugs/DB15136
    Investigational

    Rebaudioside A is under investigation in clinical trial NCT03510624 (Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus).

  4. Drug

    MC-1

    go.drugbank.com/drugs/DB05315
    Experimental

    Medicure's MC-1 drug is a cardio-protectant, designed to reduce the damage to the heart when arteries are blocked and when they are subsequently reopened after bypass surgery.

  5. Drug

    Acadesine

    go.drugbank.com/drugs/DB04944
    Investigational

    Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.

  6. Drug

    Alaproclate

    go.drugbank.com/drugs/DB13233
    Experimental

    Development was discontinued due to concerns over hepatotoxicity observed in animal studies.

  7. Drug

    Conteltinib

    go.drugbank.com/drugs/DB21262
    Investigational

    Conteltinib has a monoisotopic molecular weight of 635.34 Da.

  8. Drug

    Osunprotafib

    go.drugbank.com/drugs/DB21547
    Investigational

    Osunprotafib has a monoisotopic molecular weight of 385.15 Da.

  9. Drug

    Zelicapavir

    go.drugbank.com/drugs/DB21662
    Investigational

    Zelicapavir has a monoisotopic molecular weight of 549.17 Da.

  10. Drug

    Zoracopan

    go.drugbank.com/drugs/DB21702
    Investigational

    Zoracopan has a monoisotopic molecular weight of 614.16 Da.